Ghrelin Acetate — Dosing & Research | Peptide Chats
Research information only. Not medical advice. 18+ only. Not FDA-approved for human therapeutic use.

Ghrelin Acetate

Also known as: Acyl Ghrelin, Acylated Ghrelin, Growth Hormone Secretagogue, Motilin-Related Peptide, GHRL, Hunger Hormone, n-octanoyl-ghrelin

Endogenous 28-amino-acid octanoylated peptide hormone / growth hormone secretagogue / orexigenic gut-brain hormone

Research chemicalLast updated: November 2, 2026Based on 12 peer-reviewed studies

What it is

Ghrelin acetate is ghrelin, the natural gut hormone that drives appetite and growth hormone release, supplied as an acetate salt in freeze-dried (lyophilized) powder form for research. Researchers are studying ghrelin for cachexia and wasting in seriously ill patients; it works by signaling hunger and promoting energy storage. Not FDA-approved: ghrelin has been studied in Phase I/II trials for cachexia and GI disorders, and there is no formal human safety study of ghrelin acetate as a research compound.

The scientific side

Ghrelin acetate is the acetate-salt form of ghrelin, a 28-amino-acid peptide hormone discovered in 1999 as the endogenous ligand for the growth hormone secretagogue receptor (GHSR, specifically the GHS-R1a isoform). It is primarily secreted by oxyntic (X/A-like) cells of the gastric fundus mucosa, with smaller amounts produced in the hypothalamus, pituitary, and other tissues. Ghrelin is distinguished by a unique post-translational octanoylation: the enzyme ghrelin-O-acyltransferase (GOAT) attaches an n-octanoyl (C8) fatty acid group to the serine residue at position 3, and this acylation is essential for GHS-R1a binding and the principal hormonal activities. Unacylated (desacyl) ghrelin circulates at higher concentrations but does not activate GHS-R1a at physiological concentrations. GHS-R1a is a Gα(q/11)-coupled GPCR expressed on pituitary somatotrophs (mediating GH release), hypothalamic arcuate nucleus neurons (mediating appetite via NPY/AgRP upregulation), and widely across the brain, pancreas, adipose tissue, cardiovascular system, and immune cells. A second isoform, GHS-R1b, does not bind ghrelin independently but forms functional heterodimers with GHS-R1a that modulate signaling. Physiologically, plasma ghrelin rises preprandially, peaks just before meal initiation, and falls within 1–2 hours after eating — a pattern suggesting a role in meal initiation. Ghrelin is described as the sole circulating orexigenic hormone. Its appetite-stimulating effect is mediated in part through hypothalamic NPY and AgRP neurons. Ghrelin also promotes fat storage, reduces energy expenditure, and increases respiratory quotient. In the hippocampus, GOAT-mediated local acylation of ghrelin activates GHSR1a, upregulates cAMP and CREB phosphorylation, amplifies NMDA receptor-mediated synaptic transmission, and activates Fyn kinase — supporting adult neurogenesis and memory consolidation. In cardiac tissue, ghrelin and GHSR expression increase in diseased left ventricular tissue, suggesting a compensatory role in heart failure. A newly identified endogenous antagonist, LEAP2 (liver-expressed antimicrobial peptide 2), acts as an inverse agonist at GHS-R1a and opposes ghrelin's effects.

Class: Endogenous 28-amino-acid octanoylated peptide hormone / growth hormone secretagogue / orexigenic gut-brain hormone

Administration & storage

Administration
Intravenous infusion at 0.1 µg/kg/min for 120 min — used in heart failure RCT (PMID: 41886075)
Storage
No storage data described in reviewed abstracts. Standard peptide storage: lyophilized at -20°C; reconstituted solutions at 4°C short-term. The octanoyl acyl group is susceptible to hydrolysis by esterases at room temperature and in plasma — reduced temperature storage important for maintaining bioactive form.
Cautions
No formal human safety study reviewed for ghrelin acetate as a research compound. Safety data derive from clinical infusion trials at defined doses.,Ghrelin promotes fat storage, increases appetite, and may promote weight gain with chronic use — relevant consideration for metabolic conditions.,Short plasma half-life limits consistent systemic bioavailability with subcutaneous administration; receptor desensitization has been identified as a concern with repeated dosing.,GHS-R1a expression in pancreatic islets: ghrelin modulates insulin secretion; effects on glucose homeostasis require attention in patients with diabetes.

Legal & regulatory status

US FDA

Not approved by the US FDA for any therapeutic indication. Ghrelin has been studied in Phase I/II clinical trials for cachexia and gastrointestinal disorders but no approved product exists as of reviewed literature…

WADA

Not stated in reviewed literature as explicitly prohibited. As a growth hormone secretagogue, ghrelin and its mimetics fall under the S2 Peptide Hormones, Growth Factors, Related Substances and Mimetics category on the…

Health Canada

Not stated in reviewed literature as an approved therapeutic — requires manual verification.